Here's what's coming up this week on Contemporary OB/GYN®
The US Food and Drug Administration (FDA) has amended the emergency use authorization of the Pfizer/BioNTech vaccine to include children aged 5 to 11 years.
The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.
The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in postmenopausal patients with breast cancer.
Check baack soon for additional updates.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More